Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches
Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical prac...
Saved in:
Published in | Expert opinion on pharmacotherapy Vol. 24; no. 13; p. 1463 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
02.09.2023
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical practice other scenarios, such as switching from other oral antipsychotics or other LAIs, occur frequently, requiring guidance.
Pharmacodynamic properties of antipsychotics and their relation to rebound symptoms. Pharmacokinetic properties of LAIs and their implications for switching approaches. Specific approaches to switching to LAIs.
The LAI landscape has evolved significantly in the last decade with more formulations available, longer dosing intervals, and extended indications. However, currently available LAIs have various shortcomings, e.g. short dosing intervals, need for oral supplementation, loading regimens, deep intramuscular injection and/or restricted indications. Recent improvements include a one-day initiation option for aripiprazole lauroxil, aripiprazole monohydrate once-monthly, risperidone in situ microparticles and subcutaneous risperidone. Future LAI developments should focus on longer dosing intervals, subcutaneous administration, expansion of LAIs beyond currently available antipsychotic agents and indications beyond schizophrenia and bipolar disorder. In the future, LAIs might become a first-line treatment after initial oral stabilization for chronic mental disorders with need for maintenance treatment and presence of significant non-adherence. |
---|---|
AbstractList | Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical practice other scenarios, such as switching from other oral antipsychotics or other LAIs, occur frequently, requiring guidance.
Pharmacodynamic properties of antipsychotics and their relation to rebound symptoms. Pharmacokinetic properties of LAIs and their implications for switching approaches. Specific approaches to switching to LAIs.
The LAI landscape has evolved significantly in the last decade with more formulations available, longer dosing intervals, and extended indications. However, currently available LAIs have various shortcomings, e.g. short dosing intervals, need for oral supplementation, loading regimens, deep intramuscular injection and/or restricted indications. Recent improvements include a one-day initiation option for aripiprazole lauroxil, aripiprazole monohydrate once-monthly, risperidone in situ microparticles and subcutaneous risperidone. Future LAI developments should focus on longer dosing intervals, subcutaneous administration, expansion of LAIs beyond currently available antipsychotic agents and indications beyond schizophrenia and bipolar disorder. In the future, LAIs might become a first-line treatment after initial oral stabilization for chronic mental disorders with need for maintenance treatment and presence of significant non-adherence. |
Author | Højlund, Mikkel Correll, Christoph U |
Author_xml | – sequence: 1 givenname: Mikkel orcidid: 0000-0002-5786-5203 surname: Højlund fullname: Højlund, Mikkel organization: Child and Adolescent Mental Health Centre, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark – sequence: 2 givenname: Christoph U orcidid: 0000-0002-7254-5646 surname: Correll fullname: Correll, Christoph U organization: Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37345508$$D View this record in MEDLINE/PubMed |
BookMark | eNo1T9tKxDAUDKK4F_0EpT_QNc219U0WV4UFH9Tn5TSXbdY2CU1E9u_tojIPM8MMA7NA5z54g9BNhVcVrvFdxQSfIFYEE7oihNSiFmdoXknGSimEmKFFSgeMCW44u0QzKinjHNdz9Pn27bLqnN8XORR98PsSVD5Z5w9GZWh7U4DPLqaj6kJ2Kt0XsYNxABX6sHcK-kIFn5w2I2Q3qamuizieZk4hxDgGUJ1JV-jCQp_M9R8v0cfm8X39XG5fn17WD9tSUSFyaY2VNUhCGwqtZEC5xUYLyakBSxSrqsYaIhQzUnMDXDAplGa6biW20zGyRLe_u_GrHYzexdENMB53_6_JD8PpXcM |
CitedBy_id | crossref_primary_10_1080_14737175_2024_2325655 |
ContentType | Journal Article |
DBID | NPM |
DOI | 10.1080/14656566.2023.2228686 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-7666 |
ExternalDocumentID | 37345508 |
Genre | Journal Article Review |
GroupedDBID | --- 00X 03L 0BK 0R~ 29G 4.4 53G 5GY AAMIU AAOUU AAPWH ABBAB ABEIZ ABJNI ABJYH ABLIJ ABLKL ABVAX ABXYU ACGFS ACIEZ ADCVX ADRBQ ADTOD AECIN AENEX AEOZL AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CKQYL CS3 DASJU DAWQK DKSSO DU5 EBS EJD EMOBN F5P H13 HZ~ KRBQP KSSTO KUULJ KWAYT KYCEM LJTGL LSO M44 M4Z NPM O9- P2P RNANH TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N |
ID | FETCH-LOGICAL-c366t-fef78a72393ab74a35f0ed6753eaf2c4119fe26c4e7d5ea56476cd4d8b70f7342 |
IngestDate | Wed Oct 16 00:38:35 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | haloperidol olanzapine risperidone Antipsychotic aripiprazole paliperidone schizophrenia fluphenazine |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c366t-fef78a72393ab74a35f0ed6753eaf2c4119fe26c4e7d5ea56476cd4d8b70f7342 |
ORCID | 0000-0002-5786-5203 0000-0002-7254-5646 |
PMID | 37345508 |
ParticipantIDs | pubmed_primary_37345508 |
PublicationCentury | 2000 |
PublicationDate | 2023-09-02 |
PublicationDateYYYYMMDD | 2023-09-02 |
PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert opinion on pharmacotherapy |
PublicationTitleAlternate | Expert Opin Pharmacother |
PublicationYear | 2023 |
SSID | ssj0020954 |
Score | 2.420626 |
SecondaryResourceType | review_article |
Snippet | Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1463 |
Title | Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37345508 |
Volume | 24 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFLYKkyYuCMaAAZt8QFyKSxs7dsKNVUzVpFVIayVuKE5s1B9LKwhCcOBv5zl2frTqtMEliuLGqfy-PL3nvO97CB1DpiMFjSWBDIUTJoKYhLrtk8j3KdeQc0luiMK_-rw3ZD-v_etG46XOLslkK35eySt5j1XhGtjVsGTfYNlyUrgA52BfOIKF4fhfNv79OMpsLSREkNNZeksMTSEnqZjtlZwVBSs3clQrUxNEL5rzSq3ayYPYnp2uKM4qB-TcKaMj4DTHXanhuKzcU3dZ05Ct8oAzLSfNFlUKeuZD_PdgPH1w3YtHk4kqizq6pjWI_e5Rihw0h_WNCI_mlVbWkyrrPAVjRHDbRaXwrpYhXaCI1nwl-Gi60onbqseOUXKDYLNlntUyG1XcimbXDDv_k1uWCmrI2cG_R5e0tYuhNbQmAuMl-2avx6XrEHyygvMVtM9W_p8N9LGYYykvyeOTwRbadIkFvrAo2UYNlX5CJ1fWLE-neFAR7e5P8Qm-qlDwtIMmJZRwNsM1KOEKSngRSud4CUh4EUjw8wSXQMIVkD6j4Y_LQbdHXB8OElPOM6IVvLSRMGJ5kRQsor5uqwQyTaoi7cWs0wm18njMlEh8FfmcCR4nLAmkaGtYHW8XraezVO0jrKjq-BK8QMBDpjwtIduIQp7E4BrghugL2rOLeDO3Yis3xfIe_HXkEG1UcDxCHzS83eorhIqZ_JZb9BX47mys |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Switching+to+long-acting+injectable+antipsychotics%3A+pharmacological+considerations+and+practical+approaches&rft.jtitle=Expert+opinion+on+pharmacotherapy&rft.au=H%C3%B8jlund%2C+Mikkel&rft.au=Correll%2C+Christoph+U&rft.date=2023-09-02&rft.eissn=1744-7666&rft.volume=24&rft.issue=13&rft.spage=1463&rft_id=info:doi/10.1080%2F14656566.2023.2228686&rft_id=info%3Apmid%2F37345508&rft_id=info%3Apmid%2F37345508&rft.externalDocID=37345508 |